2025-12-29 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co. (MRK) based on the provided data:

**0. Simple Numbers:**

*   **Ticker:** MRK
*   **Company Name:** Merck & Co Inc
*   **Current Price:** $106.78
*   **5-day SMA:** 104.816
*   **20-day SMA:** 101.2865
*   **60-day SMA:** 93.3136
*   **RSI:** 71.0369
*   **PPO:** 0.3084
*   **Expected Return:** -47.6%

**1. Return Rate Comparison and Alpha/Beta Analysis:**

*   **Company Overview:** Merck & Co. Inc. is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing a broad range of healthcare solutions.
*   **MRK Cumulative Return:** 27.02%
*   **VOO (S&P 500) Cumulative Return:** 103.21%
*   **Divergence:** -80.6 (Relative Divergence: 18.5)

**Analysis:**

MRK has significantly underperformed the S&P 500 over the period examined. The large negative divergence (-80.6) highlights this. The relative divergence of 18.5 suggests that the current divergence is near the low end of its historical range relative to VOO.

The Alpha/Beta analysis table shows mixed performance across different 3-year periods. Key observations:

*   **CAGR Volatility:** The Compound Annual Growth Rate (CAGR) fluctuates considerably, ranging from -22% to 40%, highlighting inconsistency.
*   **High MDD:** The Maximum Drawdown (MDD) is consistently high (68.5%-79.6% except the last period) which means big price fluctuation so it may be the weakness of Merck, and it means more care should be taken when investing.
*   **Inconsistent Alpha:** Alpha (risk-adjusted outperformance) is highly variable, indicating inconsistent performance relative to its benchmark, with negative values in several periods.
*   **Beta near Zero:** Beta (market sensitivity) is low, generally close to zero, implying MRK's price is not strongly correlated with the market. However, the recent rise to 1.8 from 2023-2025 means that it is very sensitive to the market.
*   **Cap(B):** Market capitalization is increasing except for the last period, but recently slightly fluctuating, from 134.1B to 266.7B.

**2. Recent Stock Price Fluctuations:**

*   **Close:** $106.78
*   **Last-market Change:** +$0.31
*   **5-day SMA:** 104.816
*   **20-day SMA:** 101.2865
*   **60-day SMA:** 93.3136

**Analysis:**

The stock price is above all three moving averages, indicating a short-term upward trend. The 5-day SMA is above the 20-day SMA, which is above the 60-day SMA, confirming this bullish signal. The small change in the last market indicates that the fluctuation issue is low.

**3. RSI, PPO, and Expected Return:**

*   **MRI:** 1.0 (High Investment Recommended)
*   **RSI:** 71.04 (Overbought)
*   **PPO:** 0.3084
*   **Hybrid Signal:** Buy 100% (Very Safe)
*   **Recent Relative Divergence Change:** +1.3 (Short-term Increase)
*   **Expected Return:** -47.6%

**Analysis:**

*   **MRI Contradiction:** While the Market Risk Indicator (MRI) suggests a "High Investment Recommended," the negative expected return indicates potential risk.
*   **Overbought RSI:** The RSI above 70 suggests the stock may be overbought and could be due for a correction.
*   **Positive PPO:** A positive PPO suggests the price uptrend.
*   **Buy Signal:** Hybrid signal, based on cash_0%_Buy 100%, is recommended because of the safety, considering MRI 1.0.
*   **Divergence Change:** The increase of relative divergence implies short-term upside in MRK relative to VOO.

**4. Recent News & Significant Events:**

*   **Recent Surge:** News articles highlight a recent surge in MRK stock, partly attributed to an upgrade by BMO Capital Markets with a price target of $130.
*   **Dividend Increase:** Merck announced an increase in its dividend, which is generally positive for investors.
*   **Analyst Perspectives:** Articles discuss whether the recent rally is sustainable and whether Merck is a buy, indicating mixed analyst opinions.
*   **Institutional Activity:** Reports mention that Kempner Capital Management Inc. lowered its holdings in Merck, which can sometimes indicate concerns.
*   **Legitimacy of Stock Run:** One article questions whether the recent stock run is legitimate, reflecting caution.

**Analysis:**

The news suggests a recent positive sentiment surrounding MRK due to the price target increase and dividend announcement. However, some caution exists regarding the sustainability of the rally and institutional selling.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.90)
*   **Target Price:** $110.04 (Average)

**Analysis:**

Analysts generally rate Merck as a "Buy" with an average target price of $110.04, which is slightly above the current price. The high target price of $139.00 indicates some analysts are particularly bullish.

**5. Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2025-11-05 | 2.32 | 17.28 B$     |
| 2025-08-05 | 1.76 | 15.81 B$     |
| 2025-05-02 | 2.01 | 15.53 B$     |
| 2024-11-06 | 1.25 | 16.66 B$     |
| 2025-11-05 | 1.25 | 16.66 B$     |

**Analysis:**

*   **EPS Growth:** Earnings per share (EPS) has shown inconsistent growth. The latest EPS is significantly better than the previous year.
*   **Revenue Growth:** Revenue has also been fluctuating, but the latest quarter shows a significant increase.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30 | $17.28B  | 77.69%         |
| 2025-06-30 | $15.81B  | 77.50%         |
| 2025-03-31 | $15.53B  | 77.98%         |
| 2024-12-31 | $15.62B  | 75.50%         |
| 2024-09-30 | $16.66B  | 75.51%         |

**Capital and Profitability:**

| Quarter      | Equity    | ROE   |
|--------------|-----------|-------|
| 2025-09-30 | $51.85B  | 11.16% |
| 2025-06-30 | $48.99B  | 9.04%  |
| 2025-03-31 | $48.34B  | 10.51% |
| 2024-12-31 | $46.31B  | 8.08%  |
| 2024-09-30 | $44.50B  | 7.09%  |

**Analysis:**

*   **High Profit Margins:** Merck maintains exceptionally high profit margins (around 75-78%), indicating strong pricing power.
*   **Rising Equity:** Equity has steadily increased, reflecting growth and profitability.
*   **Improving ROE:** Return on Equity (ROE) has generally improved, suggesting that Merck is becoming more efficient in generating profits from shareholder equity.

**7. Comprehensive Analysis (Summary):**

**Overall:**

Merck presents a mixed investment picture.

**Positives:**

*   **Recent Upward Trend:** Stock is above its moving averages, indicating a short-term bullish trend.
*   **Analyst Buy Rating:** Analysts generally rate the stock as a "Buy" with a target price above the current level.
*   **High Profitability:** The company boasts exceptionally high profit margins and improving ROE, indicating a strong business model.
*   **Dividend Increase:** Recent dividend increase is positive for investors.
* **Hybrid Signal:** Hybrid signal, based on cash_0%_Buy 100%, is recommended because of the safety, considering MRI 1.0.

**Negatives:**

*   **Underperformance vs. S&P 500:** MRK has significantly underperformed the S&P 500 over the examined period.
*   **Negative Expected Return:** The significantly negative expected return of -47.6% raises concerns about future performance.
*   **High MDD:** The consistently high Maximum Drawdown (MDD) may be a weakness.
*   **Overbought RSI:** The RSI suggests the stock might be overbought, potentially leading to a correction.
*   **Mixed News Sentiment:** While recent news is largely positive, some articles question the sustainability of the rally.

**Conclusion:**

The recent surge in MRK stock driven by analyst upgrades and a dividend increase is encouraging. However, the stock's underperformance relative to the S&P 500 and the negative expected return warrant caution. The high RSI reading suggests potential for a pullback. Before making an investment decision, investors should weigh the potential upside from the analyst's price target and the recent momentum against the significant risks indicated by the negative expected return and historical underperformance. **Despite the analyst's buy rating and recent upward trend, the negative expected return raises a significant red flag and necessitates further due diligence.**


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.